Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

11,088 total articles

Buy Micron: HBM Shortage + Cash Strength Makes a High-Conviction Trade

Buy Micron: HBM Shortage + Cash Strength Makes a High-Conviction Trade

Micron sits at the center of an AI-driven memory supercycle. With HBM scarcity, fiscal Q3 revenue of $41.46B (345% YoY), a $30B cash war chest and guidance pointing to $50B next quarter, Micron can sustain a multi-quarter re-rating. This trade targets $1,800 with a $900 stop, sized for traders who can withstand elevated cyclicality and headline ris…

Graham Holdings: Deep Value, Clean Balance Sheet — A Tactical Long

Graham Holdings: Deep Value, Clean Balance Sheet — A Tactical Long

Graham Holdings (GHC) is a diversified holding company trading around $1,160 with a market cap near $5.0B, P/B ~1.04 and P/E ~16.8. Strong free cash flow, low leverage, and a mix of education, healthcare and broadcasting assets make the business defensible. We present a tactical long with an entry at $1,150, stop at $1,040 and target at $1,250 over…

Precision Drilling (PDS): Buy the Oversold Rig - 180-Day Trade Plan

Precision Drilling (PDS): Buy the Oversold Rig - 180-Day Trade Plan

Precision Drilling trades at a sub-1 PB, sits near oversold technicals (RSI ~31.6) and has a compact market cap of roughly $1.0B. I plan a long trade at the current price with a $97 target over 180 trading days and a $72 stop — a trade that balances upside from a potential re-rating and operational improvement against clear cyclical and execution r…

Precigen Poised to Monetize an Oncology Win — Tactical Long at $5.90

Precigen Poised to Monetize an Oncology Win — Tactical Long at $5.90

Precigen is showing the first signs of commercial scale after FDA approval of PAPZIMEOS: $21.6M in net product revenue in the first full quarter, permanent J-code reimbursement, broad payer coverage and a path to cash-flow break-even by year-end. The stock carries lofty valuation multiples, heavy short interest and an overbought technical reading, …

Tesla Upgrade: Two Former 'Moonshots' Turn into Real Mid-Term Catalysts

Tesla Upgrade: Two Former 'Moonshots' Turn into Real Mid-Term Catalysts

Tesla's valuation still embeds moonshot expectations, but two large initiatives - Full Self-Driving/robotaxi economics and accelerating energy storage sales - are moving from theory to measurable revenue vectors. With a $1.44T market cap, $7B of free cash flow and stretched multiples, this trade targets a measured long exposure with a mid-term hori…

Buy Pfizer on the Dip: Income Now, Re-rating Potential Later

Buy Pfizer on the Dip: Income Now, Re-rating Potential Later

Pfizer offers a rare combination today: a double-digit-ish dividend yield (above 7%), healthy free cash flow ($9.49B) and an inexpensive EV/EBITDA (~8.3x). Those attributes make a disciplined long trade attractive even as the company navigates a patent cliff and pipeline execution risk. This idea lays out an entry at $24.10, a $28 target and a $21.…

NVR: A Capital-Efficient Homebuilder Poised to Reclaim Premium Multiple

NVR: A Capital-Efficient Homebuilder Poised to Reclaim Premium Multiple

NVR has the operational profile of a conservative, cash-generative homebuilder and is trading below its 52-week high after a cyclical pullback. With ROE above 35%, FCF near $1.23B, and an asset-light land model, the company can weather high mortgage rates better than many peers. This trade targets a recovery toward $8,000 over the next 180 trading …

SkyWest: Deep-Value Regional Airline with Meaningful Upside

SkyWest: Deep-Value Regional Airline with Meaningful Upside

SkyWest trades at about a single-digit P/E and an EV/EBITDA below 7 while producing >$300M in free cash flow. The stock looks materially cheap versus its earnings power and franchise exposure to mainline capacity. Initiate a long position with a clearly defined entry, stop and target and a 180-trading-day time horizon.